key: cord-0844532-43ndibqx authors: Gornyk, D.; Harries, M.; Gloeckner, S.; Strengert, M.; Kerrinnes, T.; Bojara, G.; Castell, S.; Frank, K.; Gubbe, K.; Heise, J.-K.; Hernandez, P.; Kappert, O.; Kern, W.; Illig, T.; Klopp, N.; Maass, H.; Ortmann, J.; Kessel, B.; Roller, G.; Schlueter, M.; Tonn, T.; Ziemons, M.; Kemmling, Y.; Lange, B.; Krause, G. title: SARS-CoV-2 seroprevalence in Germany - a population based sequential study in five regions date: 2021-05-06 journal: nan DOI: 10.1101/2021.05.04.21256597 sha: 100c3257ede50142c4d3b13c8184d9c1067e54c4 doc_id: 844532 cord_uid: 43ndibqx Prevalence of SARS-CoV-2 antibodies is an essential indicator to guide measures. Few population-based estimates are available in Germany. We determine seroprevalence allowing comparison between regions, time points, socio-demographic and health-related factors. MuSPAD is a sequential multi-local seroprevalence study. We randomly recruited adults in five counties with differing cumulative SARS-CoV-2 incidence July 2020 - February 2021. Serostatus was determined using Spike S1-specific IgG ELISA. We determined county-wise proportions of seropositivity. We assessed underestimation of infections, county and age specific infection fatality risks, and association of seropositivity with demographic, socioeconomic and health factors. We found seroprevalence of 2.4 % (95%CI: 1.8-3.1%) for Reutlingen in June 2020 (stage 1) which increased to 2.9% (95%CI: 2.1-3.8%) in October (stage 2), Freiburg stage 1 1.5% (95% CI: 1.1-2.1%) vs. 2.5% (95%CI: 1.8-3.4%), Aachen stage 1 2.3% (95% CI: 1.7-3.1%) vs. 5.4% (95%CI: 4.4-6.6%), Osnabrueck 1.3% (95% CI: 1.0-1.9%) and Magdeburg in Nov/Dec 2020. 2.4% (95%CI 1.9-3.1%). Number needed to quarantine to prevent one infection was 8.2. The surveillance detection ratio (SDR) between number of infections based on our results and number reported to health authorities ranged from 2.5-4.5. Participants aged 80+ had lower SDR. Infection fatality estimates ranged from 0.2-2.4%. Lower education was associated with higher, smoking with lower seropositivity. Seroprevalence remained low until December 2020 with high underdetection. The second wave from November 2020 to February 2021 resulted in additional 2-5% of the population being infected. Detected age specific differences of SDR should be taken into account in modelling and forecasting COVID-19 morbidity. Funding: The Helmholtz Association, European Union's Horizon 2020 research and innovation programme [grant number 101003480] and intramural funds of the Helmholtz Centre for infection (HZI). (<5%). Most of these surveys were so-called hotspot studies which assessed seroprevalence after localized outbreaks or examined seroprevalence of specific population groups such as e.g. medical staff. Few studies are either population-based or blood donor-based, but do not allow comparisons between regions. To date, we only consider the Corona sub-study of the Rhineland study similar to MuSPAD. It reports a low SARS-CoV-2 seroprevalence (46/4755; 0.97%; 95% CI: 0.72−1.30). Based on this, almost the entire German population remained susceptible to a SARS-CoV-2 infection by the end of 2020. We provide the first comprehensive, high-precision multi-region population-based SARS-CoV-2 seroprevalence study with representative sampling following the WHO protocol in Germany. By measuring SARS-CoV-2 IgG, we explore immunity at regional and national level over time. We also assess risk factors and sample each region twice, which permits to monitor seroprevalence progression throughout the epidemic in different exemplary German regions. Our results show low seroprevalence (<3%) until Mid-December 2020 in all regions. While estimates in Reutlingen, Aachen, Freiburg and Osnabrück reflect low seroprevalence mostly after the first wave, the survey in Magdeburg cumulatively already represents the beginning of the second wave. The number needed to quarantine to prevent one infection was 8.2 in our study. We also show that for the first wave reported infections reflected overall around 25% of those actually infected rising to 40-50% in the second wave. A slightly raised infection risk could be shown for persons with lower education. More than one year into the pandemic, information about the actual extent of SARS-CoV-2 infections in the German population is still largely based on the number of COVID-19 cases reported to local health care authorities based on regulations of the German Infection Protection Act (IfSG). In January 2020, the first case in Bavaria, Germany was detected 1 . Shortly after, more cases occurred, many of which in North-Rhine Westphalia, linked to a carnival session 2 . In the following months several clusters occurred in Lower Saxony in meat processing facilities 3 . The first epidemic wave in spring 2020 was characterized by comparably low age-standardized case fatality estimates 4 and low excess mortality 5 . In the beginning of the pandemic the infection management focused on outbreak investigations, hotspots and PCR screenings for specific populations like health care workers. Consequently, current estimates of SARS-CoV-2 spread are not reliable as they do not include frequently occurring non-notified asymptomatic or mild SARS-COV-2 infections 6 7 . In contrast, population-based cohort studies measuring IgG antibodies can shed light on the number of persons with prior SARS-CoV-2 exposure independent of clinical manifestation and determine age specific infection fatality risk. Precise knowledge and quantification of SARS-CoV-2 seroprevalence and its development over time can aid to judge the effectiveness of population-based interventions, direct future preventive strategies and guide vaccination strategies to build herd immunity independent of natural exposure. To date there are over 30 published seroepidemiological studies in Germany, with only one general focussing on the population not based in hotspots 8 , two with populations consisting of children 9 10 and five studies among blood donors 11 12 . One of the largest studies "CORONA-MONITORING local" 13 conducted by the Robert Koch Institute, focused on recent hotspots. In Kupferzell the seroprevalence was 7.7% which implies 3.9 times more past infections than cases reported by the health authorities. Similarly, in Bad Feilnbach the seroprevalence equals 2.6 times more infections than previously known. So far, the above mentioned existing sub-cohort study conducted in Bonn, targeted the general population without aforementioned focus 8 . The sample size and methodology of these studies do not allow to provide population group specific estimates from larger non-hotspot counties and regions within Germany. To address the lack of data on the extent of SARS-CoV-2 dissemination in the general population and to allow for a better comparison with other European countries despite differing surveillance systems, we established MuSPAD (Multilocal and Serial Prevalence Study of Antibodies against SARS-2 Coronavirus in Germany). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint We followed the WHO protocol 14 for SARS-CoV-2 seroprevalence studies and STROBE as a reporting guideline for observational studies 15 . MuSPAD is an ongoing population-based seroepidemiological observational study consisting of successive cross-sectional studies with longitudinal components (follow ups within three months). Each follow-up comprises a new cross-sectional study. Main data collection period is from July 2020 until August 2021. Residents' registration offices drew a random sample taking into account age (≥18 years), gender and spatial distributions 16 . Individuals who received a written invitation, provided written informed consent and did not have contraindications for giving a blood sample were eligible for the study. All study materials were provided in German. Individuals with suspected or confirmed SARS-CoV-2 infections were not excluded. The spatial and temporal patterns of COVID 19 incidence were quite different within Germany. Initially heavily impacted was the south of Germany which is why we chose the urban and rural area of Freiburg including Breisgau-Hochschwarzwald and a county called Reutlingen in the south west. These belong to the state of Baden-Württemberg and had reported early high notified case incidences. Cumulative incidence approached 500/100,000 population in June 2020. Freiburg is a city of about 250,000 inhabitants with a surrounding rural area of Breisgau-Hochschwarzwald (hereafter referred to as Freiburg). Its defining feature in the epidemic in March 2020 was a geographic closeness to one of the hardest hit regions in France, the Alsace. It was the first city in Germany to instate severe contact restrictions, already on 18 th of March 2020. Reutlingen is a city of around 115,000 inhabitants in the south-west of Germany and has a surrounding rural area of Swabian Alb. The industrialised county of Reutlingen overall has a population of around 280,000 residents. The first COIVD-19 wave in Germany happened between March and the beginning of April 2020, in particular in north-west hotspots attributed to the carnival season. The StädteRegionAachen (around 560.000 inhabitants) (hereafter referred to as Aachen) was chosen because of its strong carnival tradition. It consists of one larger city, several rural regions, and mid-level cities and includes border regions to Belgium. When sampling a second time in Aachen, some of the residents already had been vaccinated. In the further course several COVID-19 clusters occurred in Lower Saxony, Northern Germany. We selected the urbanized and rural area of Osnabrück to sample the general population. The rural region of Osnabrück is home to several meat producing industries, where outbreaks of SARS-CoV-2 were registered from March to July 2020 ( 3 ). In the eastern part of Germany case numbers increased only slowly. Here, we chose Magdeburg with its 236.000 inhabitants as the capital of the state of Saxony-Anhalt which had only scattered outbreaks during June 2020 but started to have a second wave of cases in November 2020 (Figure 1 ). In each location a study centre was set up to enable questionnaire based interviews and blood collection of around 100-150 individuals per day. Study centres followed Standardized Operating . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) either in the study centre, or -if symptomatic, immobile or frail -with a mobile study team. Informed consent was given after explanation of study procedures and risks by trained study staff with a medical doctor present for questions. Subsequently, a questionnaire was administered and a blood sample was taken. The study participant was made aware of a follow-up questionnaire available on paper or online (web or mobile app). For data collection and follow-up the application PIA (Prospective Monitoring and Management -App) 17 was used. PIA enables the consolidation of data from different sources (study staff, participants) in real-time, simplifying data management and improving data quality. PIA complies with German data protection and IT security requirements and has been regulary evaluated by penetration tests. Additional information on recruitment procedures, questionnaires, laboratory procedures, and data protection are shared in the Supplement section. A venous blood sample of 9 mL using barcoded serum-gel monovettes was performed at the test centre or at home. After centrifugation (2500g, 10min at ambient temperature) to separate serum from cellular blood components, samples were stored at 4-8°C until analysis at the Institute for Transfusion medicine in Plauen. Spike S1 -specific IgGs were measured using the semi-quantitative SARS-CoV-2 IgG ELISA from Euroimmun (Lübeck, Germany) according to the manufactures instruction. The remaining serum was aliquoted, frozen and stored at the Hannover Unified Biobank (HUB). We estimated prevalence ratios using a 95% confidence interval (CI) using crude and population weighted 18 subgroups for age and sex per county. We further analysed the influence of other factorssuch as comorbidities, residential area and work related factors -in multivariable logistic regression analysis with variables determined in advance accounting for clustering by study site. Expected infections were calculated for each study site as the product of seroprevalence per site multiplied by inhabitants. We computed a ratio for the sensitivity of the surveillance system to detect infections (Surveillance Detection Ratio), taking the number of persons of a study region having ever been notified as SARS-CoV-2 cases (from onset of the pandemic until 14 days before blood samples were taken), and dividing it by the number of persons expected to be infected according to seroprevalence estimates as calculated above. We calculated the number needed to quarantine to find one further infection as 1 (Prevalence in the population quarantined -Prevalence in the population not quarantined). Source data for deaths were daily death counts provided by RKI with a cut off at the start . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint of the study (14 days after cases were counted). We compared this infection fatality risk calculated as notified deaths at the start of the study over expected number of persons infected according to seroprevalence to each study site. Analyses were done using STATA (Version 14 and 16) and R Version 4.0.2. We also provide estimates of seropositivity and their uncertainties accounted for the test performance by deriving their values from Bayesian hierarchical models (as in 19 ). Such models both reflect the influence of test's sensitivity and specificity on the observed numbers of seropositive study participants and account for the uncertainties tied to these test's characteristics determined from the diagnostic accuracy. These estimates were provided as a sensitivity analysis and not used for the main estimations (Supplement). The role of the funding source The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. The first four authors had full access to all data in the study. The first two authors (DG, MH) and two senior (BL, GK) authors had final responsibility for the decision to submit the publication. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 6, 2021. We recruited 13,045 participants for stage 1 and 6,160 new participants (excluding follow-up participants) in stage 2 ( Figure 2 ) with age ranging from 18 to 99 years (median 51), 55% of which female. Proportions of self-reported chronic conditions were similar across regions and stages (overall 26.0% hypertension, 10.4% cardiovascular disease, 8.3% chronic lung disease, 6.1% diabetes and 2.5% cancer (stage 1)) except for Magdeburg with slightly higher proportions for diabetes, hypertension and cardiovascular disease (Tabel 2). Proportion of daily smokers ranged from 10.1% in Freiburg to 16 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. (n=50)). In Reutlingen 2 in the age group 18-25 years we observed a decrease from the weighted seroprevalence 4.6% to 1.5%. The increase in weighted seroprevalence was highest among the > 79 age group. In Table 5 we report the unweighted seroprevalences. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint For stage 1 sixty-two percent (68/110) of those reporting ever having tested positive with a SARS-CoV-2 PCR had a positive antibody test in our sample. Nine percent (1/11) in Reutlingen, 25% (4/16) in Freiburg, in Aachen 35% (5/14) , in Osnabrück 35% (6/17) and in Magdeburg 7% (2/28) were not detected by serological investigation. Of those with confirmed SARS-CoV-2 infections since February 2020 95% (65/68) suffered from symptoms compatible with COVID-19, while of those seropositive 74% (81/110) had symptoms (Supplement Table 1 ). For stage 2 80% (90/112) of those reporting ever having tested positive in a SARS-CoV-2 PCR had a positive antibody test. We express surveillance sensitivity as ratio of reported cases over infected cases as detected by our serological analysis. Ratios were 3.8 in Reutlingen, 2.2 in Freiburg, 4.9 in Aachen, 2.8 in Osnabrück and 5.1 in Magdeburg. For stage 2 the ratios were in 3.5 in Reutlingen 2, 2.2 in Freiburg 2, and 2.4 in Aachen 2. Surveillance detection ratio (SDR) across age groups were heterogeneous and had large CIs with lower detection ratios in the age group >79 ( Figure 3B ). Infection fatality estimates were 1.4% in Reutlingen (95%CI 1.1-1.8%), 2.4% in Freiburg (95%CI 1.7-3.3%); 1% in Aachen (95%CI 0.7-1.3%), 1.2% in Osnabrück (95% CI 0.8-1.6%) and 0.3% in Magdeburg (95% CI 0.2-0.4%). Infection fatality estimates were highest in the oldest age group (>79) and decreased in younger age groups. In stage 2 the infection fatality estimates were 1.2% in Reutlingen2 (95%CI 0.9-1.6%); 1.7% in Freiburg 2 (95%CI 1.2-2.3%) and 1.2% in Aachen 2 (95%CI 1.0-1.4%) for more details see Figure 3 C and Table 6 . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Overall the prevalence of SARS-CoV-2 IgG antibodies was 2% (254/13,045) for all sites between July and December 2020. 14.3% of those who had been ordered to mandatory quarantine were seropositive, in contrast to 1.2% of those who had not been in quarantine. This indicates a number needed to quarantine of 8.2 persons to prevent one person from infecting other people. In a logistic regression participants reporting two of the typical COVID-19 symptoms (cough, anosmia, respiratory distress, fever and fatigue) during the last few months were associated with higher odds of being seropositive (aOR 3.6, 95%CI 3.2 -4.3) (Tabel 7). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint A logistic regression on population weighted seropositivity estimates accounting for clustering by study region showed evidence towards a higher risk of seropositive results in participants with lower education compared to higher education (aOR 1.8, 95%CI 1.2-2.7) . There was lower risk of having a seropositive result in those who smoked daily (aOR 0.5, 95%CI 0.3-0.7). Age, rural or urban location, change and type of employment as well as further predisposing conditions did not change the odds of seropositivity in our analysis (Table 8) . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint Underreporting of cases and deaths during the COVID-19 pandemic has been a major problem of public health systems around the world 4 . We present first results from five counties in Germany of an ongoing population-based seroprevalence study. Weighted seroprevalence estimates ranged from 1.4% to 2.5% in different German regions between July and December 2020 and rose to 5.4% in February 2021. Detection ratios as a measure of surveillance infection sensitivity of those reported to authorities over those infected calculated from seroprevalence ranged from 2.5 to 4.5. Detection ratios were lower between December 2020 and February 2021 than during the first months of the pandemic. Infection fatality estimates ranged from 0.2 to 2.4%. The number needed to quarantine to prevent one person from infecting others for official contact investigations of public health agencies was 8 persons for the first wave. Strengths of our seroprevalence study include its large sample size per region, the multilocal approach, as well as the random population-based sampling strategy. Limitations include the serial design in that it does not measure seroprevalence in all places at the same time. This means that compared to the measurements from July 2020 (three months after the peak of the epidemic) more antibody waning has taken place in those regions sampled later and up to major infection dynamics of the second wave in October/ November 2020. An additional limitation is since we did not include individuals younger than 18 years of age, our results can only be generalised for the adult population. All study materials were only provided in German and sufficient knowledge of the language was required to give written informed consent. Hence, this study cannot detect possible differences in the subgroup of the German population that does not fulfil these requirements. Still, we believe that five main conclusions can be drawn from the estimates presented: (mirroring detection ratios 2-2.5 in our study) in most age groups and sites. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint Second, seroprevalences between study regions were not highly variableconsiderably different in our study. This is in contrast to early hotpot studies mostly conducted in smaller German communities highly affected by the pandemic indicating large regional differences 20 . For the initial sampling periods in Freiburg, Reutlingen, Aachen, and Osnabrück, the majority of reported cases that accounts for the determined population seroprevalence was infected during the first wave. In contrast most of the seroprevalence found in Magdeburg in November 2020 is likely to already represent the beginning of the second pandemic wave. Reutlingen and Freiburg similarly show already rising seroprevalences during November and December 2020 and rapidly rising seroprevalence in February in Aachen reflecting the second wave dynamic. Third, there are few determinants of seropositivity in our study. Some evidence suggests that education is a determinant of higher risk of seropositivity. Low education and related factors (SES, change in employment) have previously been shown to explain the individual potential to isolate at home or not 23 . As previous studies have reported 24 seroprevalence among smokers was lower than among non-smokers. The explanation is unclear and may both be behaviour or physiology related. This finding has to be seen in light of the strong evidence of smoking being a risk factor for progression to more severe course of disease 25 . Fourth, age-specific estimates provided here, such as underreporting ratios and infections fatality estimates are heterogeneous across regions. Regional estimates are therefore crucial to provide a clear picture to stakeholders. Our age-specific infection fatality estimates are very much in line with previously reported estimates. The low overall infection fatality estimate in Magdeburg is largely explained by seroprevalence reflecting the early rising of cases during the second wave and our cutoff point for reported deaths being too early to show actual infection fatality. We included 15 deaths up to 15 November 2020, but 48 were notified up to 31 st December 2020. To our knowledge, our study is the first to assess regional and age specific differences in Surveillance Detection Ratio ranging from 25% to 50% between cities and overall being 2-fold higher among > 79 year olds (first wave) compared to the rest of the adult population, meaning that older people were more easily detected by notifications than younger people. We believe this to be of relevance for improving forecasting and modelling efforts and guiding risk assessment on targeted prevention measures. In how far this age specific difference detected in our study explains fast spillover of epidemic activity during the second wave in several European countries into older age groups with relatively higher epidemic activity in younger age groups should be evaluated in future modelling efforts. Fifth, we show high contact tracing efficiency with a number needed to quarantine of 8 for quarantine mandated by officials. This is in line with estimates of secondary attack rates ranging from 7.2% in those not living in the same household to 13.0% of those living in the same household 26 . In comparison . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint to the number needed to quarantine of population wide contact measures this is low -there is little evidence to interpret how this compares to other countries and their contact tracing programs. In our analysis participants having had contact with a confirmed COVID-19 case were six times more likely to be seropositive compared to those without. Several mathematical studies [27] [28] [29] showed that efficient contact tracing and case isolation reduce the COVID-19 risk. Furthermore, participants who reported a household member with positive SAR-CoV-2 PCR test result were highly associated (aOR 52.6) with SARS-CoV-2 seropositivity. All this implies that control measurement of physical distancing and mandatory quarantine are effective tools to prevent the spread of disease. We have presented results from a large ongoing seroprevalence study from several regions in Germany with already more than 19.000 participants indicating overall low seroprevalence from July to December 2020 and rising seroprevalence from December 2020 to February 2021 with comparably high infection fatality risks in particular in the old. Given the heterogeneity in underreporting estimates, we recommend that forecasting efforts use regional age-specific underreporting ratios if available to predict severe courses of disease as well as deaths more in detail. We also recommend that testing and tracing efforts be targeted in particular to those younger and middle-aged adult groups that seem to be prone to highest underreporting in our study. Gérard Krause had the idea for the study. Berit Lange was responsible for the epidemiological study . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint Gottfried Roller, Michael Ziemons and Oliver Kappert provided local support and logistical planning on the ground and supported the interpretation of the local data. All authors provided input into the first draft manuscript and all authors revised subsequent versions. Firstly, we sincerely thank counties and cities (Reutlingen, Freiburg/Breisgau Hochschwarzwald, Aachen, Osnabrück and Magdeburg) supporting and endorsing our study. We sincerely thank colleagues from the local public health departments for providing data in their districts. We are grateful to Anne Ulrike Marzian, Angelika Rath, Christina Suckel and Nicole Grupe for entering the data and answering the participant's questions and concerns. We thank our colleagues in the Plauen and Osnabrück laboratories for the laboratory analyses. We thank Astrid Hans for administrative support. We thank Neha Warikoo for providing software assistance. We thank Kevin Grigorian and the Johanniter-Unfall-Hilfe, and Tim Balz and BOS112 for collaborating with us. We also thank Armgard Zindler and Marco Krischok and IPSOS for excellent technical appointment assistance. Our greatest thanks goes to all participating persons for donating their blood and time. This work was supported by The Helmholtz Association, European Union's Horizon 2020 research and innovation programme [grant number 101003480] and by intramural funds of the HZI. The data used for this study can be made available anonymized to other academic researchers. Available data variables shared with the applicant will be: study site information, recruitment status, essay information, bio sample type, demographic information, self-administered diagnostic anamneses and seroprevalence test results. For more details please contact muspad@helmholtzhzi.de. Academic institutions can apply for the data via serohub@helmholtz-hzi.de. The serohub is the seroprevalence virtual research environment that stores case based information of the MuSPAD study and other (inter-)national studies. The application process includes the review of the targeted research question and research method. After approval, a link to share the data will be send to the applicant. Shared data will be in regards to international data standards (for more details see https://www.covid19dataportal.org/support-data-sharing-covid19 in csv format. 1. Böhmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. 2020;20 (8):920-28. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 6, 2021. ; https://doi.org/10.1101/2021.05.04.21256597 doi: medRxiv preprint Genetic structure of SARS-CoV-2 reflects clonal superspreading and multiple independent introduction events SARS-CoV-2 outbreak investigation in a German meat processing plant The role of age distribution, time lag between reporting and death and healthcare system capacity on case fatality estimates of Assessing Excess Mortality in Times of Pandemics Based on Principal Component Analysis of Weekly Mortality Data--The Case of Asymptomatic cases in a family cluster with SARS-CoV-2 infection Transmission of 2019-nCoV infection from an asymptomatic contact in Germany Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn Hospital Admission in Children and Adolescents With COVID-19: Early Results From a National Survey Conducted by the German Society for Pediatric Infectious Diseases (DGPI) Public health antibody screening indicates a six-fold higher SARS-CoV-2 exposure rate than reported cases in children SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic Seroepidemiologische Studie zur Verbreitung von SARS-CoV-2 in der Bevölkerung an besonders betroffenen Orten in Deutschland-Studienprotokoll von CORONA-MONITORING lokal Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Response in individuals with and without foreign background and application to the National Cohort in Germany: which factors have an effect? Prospective assessment of Incident health events -App 2021 Statistische Ämter des Bundes und der Länder. Bevölkerung nach Geschlecht und Altersjahren (79) -Stichtag 31.12. -(ab 2011) regionale Tiefe: Kreise und krfr. Städte Bayesian analysis of tests with unknown specificity and sensitivity German and international studies on SARS-CoV-2 seroprevalence Serology-and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study) SARS-CoV-2 Studien in der Allgemeinbevölkerung-Erkenntnisgewinn für den weiteren Pandemieverlauf in Deutschland Socioeconomic disparities in subway use and COVID-19 outcomes Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis The effect of smoking on COVID-19 severity: A systematic review and meta-analysis The epidemiological impact of the NHS COVID-19 App Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study Bidirectional contact tracing could dramatically improve COVID-19 control Isolation and contact tracing can tip the scale to containment of COVID-19 in populations with social distancing